Leprosy post-exposure prophylaxis risks not adequately assessed. by Lockwood, Diana NJ et al.
Correspondence
www.thelancet.com/lancetgh   Vol 9   April 2021 e400
Leprosy post-exposure 
prophylaxis risks not 
adequately assessed
We thank Jan Richardus and colleagues 
for their feasibility study of single-dose 
rifampicin for contacts of individuals 
diagnosed with leprosy.1 Single-dose 
rifampicin was incorporated into the 
WHO Guidelines for the Diagnosis, 
Treatment and Prevention of Leprosy 
as a conditional recommendation 
based on moderate evidence.2 The 
roadmap for neglected tropical diseases 
2021–30 targets leprosy for elimination 
(interruption of transmission) with 
single-dose rifampicin as a “core 
strategic intervention”.3 We have 
raised our concerns about single-dose 
rifampicin previously.4
R i c h a r d u s  a n d  c o l l e a g u e s 
acknowledge that single-dose 
rifampicin’s 57% protective effect 
only lasts for 2 years, and contacts of 
those with multibacillary disease only 
have 24% protection.1 Individuals 
receiving single-dose rifampicin 
need to understand the temporary 
and limited effect against leprosy. 
The Article has insufficient detail to 
determine whether fully informed 
consent of the participants was 
obtained in all centres. Brazilians were 
reportedly told, “There is leprosy in 
your area, and that is why we offer 
people preventive treatment against 
leprosy” when being informed about 
the Leprosy post-exposure prophylaxis 
(LPEP) study, without indicating the 
temporary and partial effect of single-
dose rifampicin.5
The definition of contacts in this 
study differed from that in the COLEP 
cluster randomised controlled trial 
in Bangladesh.6 In Richardus and 
colleagues’ study, contacts were given 
single-dose rifampicin up to 2 years 
after diagnosis of the index case; 
whereas, in the COLEP study, single-
dose rifampicin was given to contacts 
of newly diagnosed index cases.6 
The paediatric proportion of index 
leprosy cases was high in India (31·3%) 
and Nepal (28·7%), compared with 
reported national rates of 6·8% 
and 7·6%, respectively.7 The high 
proportion of cases in children resulted 
in a lower proportion of multibacillary 
cases (28·9%) in India than the 
national rate of 54·2%.7 These unusual 
leprosy cohorts and the variation 
in the selection of contacts mean 
that the results are not generalisable. 
The main outcome measure was the 
number of single-dose rifampicin 
given. No evaluation of the effect of 
this intervention on leprosy rates is 
planned.
WHO advises that tuberculosis needs 
to be excluded in patients before 
administering single-dose rifampicin 
to reduce the risk of producing 
rifampicin-resistant M tuberculosis 
strains.2 Screening individuals for 
tuberculosis using clinical symptoms 
before administering single-dose 
rifampicin lacks sensitivity. Only one 
Indian participant (of 42 333 screened) 
was excluded on a suspicion of 
tuberculosis in a state with a reported 
incidence rate of 194 per 100 000 
in 2019.8 This low exclusion rate 
suggests that some leprosy control 
programmes cannot effectively screen 
for tuberculosis. The widespread use of 
single-dose rifampicin might promote 
the development of Mycobacterium 
leprae rifampicin resistance. The 
risk of M tuberculosis developing 
rifampicin resistance has not been 
assessed rigorously, it was deemed 
to be negligible by an expert group 
convened by the Novartis foundation 
and the LPEP group, without a 
systematic review. The authors 
extrapolate their interpretation of the 
risk of M tuberculosis resistance data 
to M leprae, but this is not described.9 
WHO have recommended multidrug 
therapy for patients with leprosy since 
1982, to reduce the risk of rifampicin 
resistance.10 The presence of M leprae 
rifampicin resistance genes has already 
been detected.11 Dispensing millions 
of doses of single-dose rifampicin 
might jeopardise the effectiveness 
of the key antibacterial component 
of leprosy multidrug therapy. This 
policy recommendation undermines 
the global strategy to combat 
antimicrobial resistance.
Richardus and colleagues’ study 
shows that with active case finding, 
many people with leprosy are found 
and at rates greater than the reported 
national statistics.7 The Brazilian 
Ministry of Health, following wide 
consultation, has decided not to 
implement single-dose rifampicin 
because of lack of evidence for its 
efficacy.12 Brazil has the second highest 
case numbers globally and was an 
LPEP study site. the diagnosis and 
management of people with leprosy 
should be prioritised rather than the 
short-lived, partial efficacy of single-
dose rifampicin for contacts. WHO 
should review their recommendation 
to implement this intervention 
and the Global Leprosy Programme 
and other advocates of single-dose 
rifampicin should ensure robust 
mechanisms are in place to detect 
adverse effects of this policy.
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